Chen Zhixue,Dong Rui.Advances in the treatment of hepatoblastoma[J].Journal of Clinical Pediatric Surgery,2020,19(05):398-403.[doi:10.3969/j.issn.1671-6353.2020.05.005]
肝母细胞瘤多学科治疗方案的研究进展
- Title:
- Advances in the treatment of hepatoblastoma
- Keywords:
- Liver Neoplasms; Therapy; Targeted Therapy; Immunotherapy
- 分类号:
- R726;R735.7;R730.51
- 摘要:
- 肝母细胞瘤（hepatoblastoma，HB）是胚胎性肿瘤的一种，恶性程度较高，好发于3岁以下儿童。手术切除为HB首选治疗方案，手术切除的完整性关系到肿瘤预后。HB对化疗敏感，可辅助化疗、放疗等治疗手段。目前主流化疗方案为C5V（cisplatin+5-Fluorouracil+vincristine，顺铂+5-氟尿嘧啶+长春新碱）方案。对难治性HB可实施肝移植，且自体肝移植术在临床上已有成功案例。此外，靶向治疗（如针对NK1R及PI3K/Akt等通路的靶向药物治疗）已进入临床试验，而免疫治疗尚处于研发阶段。
- Abstract:
- Hepatoblastoma (HB) is a type of embryonal tumor of high malignancy usually occurring in children under 3 years of age.Surgical resection is the preferred option for HB.Complete surgical resection means better prognosis for tumor.Due to its sensitivity to chemotherapy,it can be treated by chemotherapy,radiotherapy and other treatment means.Currently,the mainstream chemotherapy program is C5V.Liver transplantation can be used for refractory HB,and there have been successful cases of autologous liver transplantation.In addition,targeted therapies,such as targeted drugs targeting NK1R and PI3K/Akt pathway,have entered clinical trials,and immunotherapy is still in the development stage.
参考文献/References:
1 Sunil BJ,Palaniappan R,Venkitaraman B,et al.Surgical Resection for Hepatoblastoma-Updated Survival Outcomes[J].J Gastrointest Cancer,2018,49(4):493-496.DOI:10.1007/s12029-017-0005-z.
2 Allan BJ,Parikh PP,Diaz S,et al.Predictors of survival and incidence of hepatoblastoma in the paediatric population[J].HPB (Oxford),2013,15(10):741-746.DOI:10.1111/hpb.12112.
3 Duan XF,Zhao Q.Adult hepatoblastoma:a review of 47 cases[J].ANZ J Surg,2018,88(1-2):E50-e54.DOI:10.1111/ans.13839.
4 中国抗癌协会小儿肿瘤专业委员会,中华医学会小儿外科分会肿瘤专业组.儿童肝母细胞瘤多学科诊疗专家共识(CCCG-HB-2016)[J].中华小儿外科杂志,2017,38(10):733-739.DOI:10.3760/cma.j.issn.0253-3006.2017.10.003. Chinese Anti-Cancer Association Pediatric Committee,China Mdical Association Pediatric Onco-surgrey Group.Expert Consensus for Multidiscciplinary Management of Hepatoblastoma(CCCG-HB-2016)[J].Chin J Pediatr Surg,2017,38(10):733-739.DOI:10.3760/cma.j.issn.0253-3006.2017.10.003.
5 Fonseca A,Gupta A,Shaikh F,et al.Extreme hepatic resections for the treatment of advanced hepatoblastoma:Are planned close margins an acceptable approach?[J].Pediatr blood cancer,2018,65(2):e26820.DOI:10.1002/pbc.26820.
6 Souzaki R,Kawakubo N,Matsuura T,et al.Navigation surgery using indocyanine green fluorescent imaging for hepatoblastoma patients[J].Pediatr Surg Int,2019,35(5):551-557.DOI:10.1007/s00383-019-04458-5.
7 Yamada Y,Hoshino K,Mori T,et al.Metastasectomy of Hepatoblastoma Utilizing a Novel Overlay Fluorescence Imaging System[J].J Laparoendosc Adv Surg Tech A,2018,28(9):1152-1155.DOI:10.1089/lap.2017.0735.
8 Yamamichi T,Oue T,Yonekura T,et al.Clinical application of indocyanine green (ICG) fluorescent imaging of hepatoblastoma[J].Journal of pediatric surgery,2015,50(5):833-836.DOI:10.1016/j.jpedsurg.2015.01.014.
9 Ramos-Gonzalez G,Laquaglia M,O’Neill AF,et al.Long-term outcomes of liver transplantation for hepatoblastoma:A single-center 14-year experience[J].Pediatric transplantation,2018,e13250.DOI:10.1111/petr.13250.
10 Fuchs J,Cavdar S,Blumenstock G,et al.POST-TEXT III and IV Hepatoblastoma:Extended Hepatic Resection Avoids Liver Transplantation in Selected Cases[J].Annals of surgery,2017,266(2):318-323.DOI:10.1097/sla.0000000000001936.
11 Shi SJ,Wang DL,Hu W,et al.Ex vivo liver resection and autotransplantation with cardiopulmonary bypass for hepatoblastoma in children:A case report[J].Pediatric transplantation,2018,22(7):e13268.DOI:10.1111/petr.13268.
12 张明满,宁禹,李英存,等.自体肝移植治疗婴幼儿复杂肝母细胞瘤一例及文献复习[J].中华小儿外科杂志,2018,39(1):44-49.DOI:10.3760/cma.j.issn.0253-3006.2018.01.010. Zhang MM,Ning Y,Li YC,et al.Applicationantologous liver transplantation in complex infantile hepatoblastoma:a report of one case[J].Chin J Pediatr Surg,2018,39(1):44-49.DOI:10.3760/cma.j.issn.0253-3006.2018.01.010.
13 Namgoong JM,Choi JU,Hwang S,et al.Pediatric living donor liver transplantation with homograft replacement of retrohepatic inferior vena cava for advanced hepatoblastoma[J].Ann Hepatobiliary Pancreat Surg,2019,23(2):178-182.DOI:10.14701/ahbps.2019.23.2.178.
14 Shinkai M,Mochizuki K,Kitagawa N,et al.Usefulness of a recanalized umbilical vein for vascular reconstruction in pediatric hepatic surgery[J].Pediatr Surg Int,2016,32(6):553-558.DOI:10.1007/s00383-016-3893-2.
15 Isono K,Ohya Y,Lee KJ,et al.Pretransplant trends in alpha-fetoprotein levels as a predictor of recurrence after living donor liver transplantation for unresectable hepatoblastoma:A single-institution experience[J].Pediatric transplantation,2018,22(5):e13221.DOI:10.1111/petr.13221.
16 Van Dalen EC,Raphael MF,Caron HN,et al.Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer[J].Cochrane Database Syst Rev,2014,4(9):Cd006647.DOI:10.1002/14651858.CD006647.
17 柳龚堡,刘百慧,李凯,等.C5V作为首选化疗方案治疗肝母细胞瘤效果观察[J].中华儿科杂志,2015,53(2):119-123.DOI:10.3760/cma.j.issn.0578-1310.2015.02.011. Liu GB,Liu BH,Li K,et al.Outcome of hepatoblastoma:experience with 63 patients received chemotherapy with the regimen C5V[J].Chinese Journal of Pediatrics,2015,53(2):119-123.DOI:10.3760/cma.j.issn.0578-1310.2015.02.011.
18 Katzenstein HM,Furman WL,Malogolowkin MH,et al.Upfront window vincristine/irinotecan treatment of high-risk hepatoblastoma:A report from the Children’s Oncology Group AHEP0731 study committee[J].Cancer,2017,123(12):2360-2367.DOI:10.1002/cncr.30591.
19 常健,张语桐,王立哲,等.顺铂单剂治疗儿童肝母细胞瘤[J].中华小儿外科杂志,2011,32(10):737-740.DOI:10.3760/cma.j.issn.0253-3006.2011.10.005. Chang J,Zhang YT,Wang LZ,et al.Single-agent of cisplatin in pretreatment of hepatoblastoma[J].Chinese journal of pediatric surgery,2011,32(10):737-740.DOI:10.3760/cma.j.issn.0253-3006.2011.10.005.
20 Wei M,Yuan X.Cisplatin-induced Ototoxicity in Children With Solid Tumor[J].J Pediatr Hematol Oncol,2019,41(2):e97-e100.DOI:10.1097/mph.0000000000001282.
21 Brock PR,Maibach R,Childs M,et al.Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss[J].N Engl J Med,2018,378(25):2376-2385.DOI:10.1056/NEJMoa1801109.
22 Morcrette G,Hirsch TZ,Badour E,et al.APC germline hepatoblastomas demonstrate cisplatin-induced intratumor tertiary lymphoid structures[J].Oncoimmunology,2019,8(6):e1583547.DOI:10.1080/2162402x.2019.1583547.
23 Beck A,Eberherr C,Hagemann M,et al.Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma[J].Cancer Biol Ther,2016,17(11):1168-1176.DOI:10.1080/15384047.2016.1235664.
24 Zhen N,Jin L,Ma J,et al.Ginsenoside Rg1 impairs homologous recombination repair by targeting CtBP-interacting protein and sensitizes hepatoblastoma cells to DNA damage[J].Anticancer Drugs,2018,29(8):756-766.DOI:10.1097/cad.0000000000000646.
25 姜程远,卜云芳.经导管动脉化疗栓塞术治疗巨大肝母细胞瘤疗效及安全性[J].现代仪器与医疗,2017,23(3):23-24.DOI:10.11876/mimt201703011. Jiang CY,Bu YF.Efficacy and safety of transcranial arterial chemoembolization in the treatment of giant hepatoblastoma[J].Modern instruments and medical treatment,2017,23(3):23-24.DOI:10.11876/mimt201703011.
26 Salem R,Lewandowski RJ,Mulcahy MF,et al.Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres:a comprehensive report of long-term outcomes[J].Gastroenterology,2010,138(1):52-64.DOI:10.1053/j.gastro.2009.09.006.
27 Lungren MP,Towbin AJ,Roebuck DJ,et al.Role of interventional radiology in managing pediatric liver tumors:Part 1:Endovascular interventions[J].Pediatric radiology,2018,48(4):555-564.DOI:10.1007/s00247-018-4068-1.
28 Liu B,Zhou L,Huang G,et al.First Experience of Ultrasound-guided Percutaneous Ablation for Recurrent Hepatoblastoma after Liver Resection in Children[J].Scientific reports,2015,18(5):16805.DOI:10.1038/srep16805.
29 朱海涛,肖现民.PI3K/Akt信号通路与小儿恶性实体肿瘤研究进展[J].临床小儿外科杂志,2009,8(6):57-59.DOI:10.3969/j.issn.1671-6353.2009.06.020. Zhu HT,Xiao XM.Research progress of PI3K/Akt signaling pathway and malignant solid tumors in children[J].J Clin Ped Sur,2009,8(6):57-59.DOI:10.3969/j.issn.1671-6353.2009.06.020.
30 Molina L,Yang H,Adebayo Michael AO,et al.mTOR inhibition affects Yap1-beta-catenin-induced hepatoblastoma growth and development[J].Oncotarget,2019,10(15):1475-1490.DOI:10.18632/oncotarget.26668.
31 乔国梁.PI3K-Akt信号通路在肝母细胞瘤的作用及肝母细胞瘤预后危险因素的评估[D].北京协和医学院,2015. Qiao GL.The role of P13K-Akt Pathway in Hepatoblastoma and Evaluation of Prognostic Risk Factors of Patients with Hepatoblastoma[D].Peking union medical college,2015.
32 Zhang C,Jia X,Wang K,et al.Polyphyllin VII Induces an Autophagic Cell Death by Activation of the JNK Pathway and Inhibition of PI3K/AKT/mTOR Pathway in HepG2 Cells[J].PloS one,2016,11(1):e0147405.DOI:10.1371/journal.pone.0147405.
33 Fu H,Zhang J,Pan T,et al.miR378a enhances the sensitivity of liver cancer to sorafenib by targeting VEGFR,PDGFRbeta and cRaf[J].Molecular medicine reports,2018,17(3):4581-4588.DOI:10.3892/mmr.2018.8390.
34 Cui Y,Lu P,Song G,et al.Involvement of PI3K/Akt,ERK and p38 signaling pathways in emodin-mediated extrinsic and intrinsic human hepatoblastoma cell apoptosis[J].Food Chem Toxicol,2016,(92):26-37.DOI:10.1016/j.fct.2016.03.013.
35 Stafman LL,Williams AP,Marayati R,et al.PP2A activation alone and in combination with cisplatin decreases cell growth and tumor formation in human HuH6 hepatoblastoma cells[J].PloS one,2019,14(4):e0214469.DOI:10.1371/journal.pone.0214469.
36 Deng S,Tang S,Zhang S,et al.Furazolidone induces apoptosis through activating reactive oxygen species-dependent mitochondrial signaling pathway and suppressing PI3K/Akt signaling pathway in HepG2 cells[J].Food Chem Toxicol,2015,(75)173-186.DOI:10.1016/j.fct.2014.11.019.
37 Perugorria MJ,Olaizola P,Labiano I,et al.Wnt-beta-catenin signalling in liver development,health and disease[J].Nat Rev Gastroenterol Hepatol,2019,16(2):121-136.DOI:10.1038/s41575-018-0075-9.
38 Indersie E,Lesjean S,Hooks KB,et al.MicroRNA therapy inhibits hepatoblastoma growth in vivo by targeting beta-catenin and Wnt signaling[J].Hepatology communications,2017,1(2):168-183.DOI:10.1002/hep4.1029.
39 Ellerkamp V,Lieber J,Nagel C,et al.Pharmacological inhibition of beta-catenin in hepatoblastoma cells[J].Pediatric surgery international,2013,29(2):141-149.DOI:10.1007/s00383-012-3237-9.
40 Godeke J,Maier S,Eichenmuller M,et al.Epigallocatechin-3-gallate inhibits hepatoblastoma growth by reactivating the Wnt inhibitor SFRP1[J].Nutrition and cancer,2013,65(8):1200-1207.DOI:10.1080/01635581.2013.828085.
41 Munoz M,Rosso M,Covenas R.The NK-1 receptor:a new target in cancer therapy[J].Curr Drug Targets,2011,12(6):909-921.DOI:10.2174/138945011795528796.
42 Berger M,Neth O,Ilmer M,et al.Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo[J].Journal of hepatology,2014,60(5):985-994.DOI:10.1016/j.jhep.2013.12.024.
43 Ilmer M,Garnier A,Vykoukal J,et al.Targeting the Neurokinin-1 Receptor Compromises Canonical Wnt Signaling in Hepatoblastoma[J].Molecular cancer therapeutics,2015,14(12):2712-2721.DOI:10.1158/1535-7163.Mct-15-0206.
44 Garnier A,Ilmer M,Kappler R,et al.Therapeutic Innovations for Targeting Hepatoblastoma[J].Anticancer research,2016,36(11):5577-5792.DOI:10.21873/anticanres.11143.
45 Baeuerle PA,Gires O.EpCAM (CD326) finding its role in cancer[J].British journal of cancer,2007,96(3):417-423.DOI:10.1038/sj.bjc.6603494.
46 Armeanu-Ebinger S,Hoh A,Wenz J,et al.Targeting EpCAM (CD326) for immunotherapy in hepatoblastoma[J].Oncoimmunology,2013,2(1):e22620.DOI:10.4161/onci.22620.
47 Ortiz MV,Roberts SS,Glade Bender J,et al.Immunotherapeutic Targeting of GPC3 in Pediatric Solid Embryonal Tumors[J].Front Oncol,2019,26(9):108.DOI:10.3389/fonc.2019.00108.
48 Tsuchiya N,Hosono A,Yoshikawa T,et al.Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors[J].Oncoimmunology,2017,7(1):e1377872.DOI:10.1080/2162402x.2017.1377872.
49 Shimizu Y,Suzuki T,Yoshikawa T,et al.Next-Generation Cancer Immunotherapy Targeting Glypican-3[J].Front Oncol,2019,10(9):248.DOI:10.3389/fonc.2019.00248.
相似文献/References:
[1]高会江,董蒨,江布先,等.26例婴儿肝脏肿瘤的临床与病理相关性分析[J].临床小儿外科杂志,2010,9(06):422.
GAO Hui jiang,DONG Qian,JIANG Bu xian,et al.Clinicopathological correlative analysis in infants with liver tumor.[J].Journal of Clinical Pediatric Surgery,2010,9(05):422.
[2]曹国庆 汤绍涛杨瑛李时望毛永忠王勇.腹腔镜治疗直肠乙状结肠型先天性巨结肠122例疗效分析[J].临床小儿外科杂志,2011,10(01):0.
CAO Guo qing,TANG Shao tao,YANG Ying et al..The clinical analysis of laparoscopic transanal puuthrough operation for rectosigmoild Hirschsprung disease (122 cases report).[J].Journal of Clinical Pediatric Surgery,2011,10(05):0.
[3]陆良生阮双岁毕允力陆毅群王翔葛琳娟肖现民.45例两性畸形患儿的诊断及治疗分析[J].临床小儿外科杂志,2011,10(01):0.
[4]刘鸿坚杨传民祁泳波王千于丹张晋绥张强李伟李友.经肛门改良Soave术治疗先天性巨结肠80例疗效分析[J].临床小儿外科杂志,2011,10(01):0.
[5]景登攀张根领孙蔓丽.改良Snodgrass术治疗尿道下裂疗效观察[J].临床小儿外科杂志,2011,10(01):0.
[6]许瑞江
洪锡伟
于向华
李文超.大年龄儿童发育性髋脱位术后再脱位的治疗[J].临床小儿外科杂志,2010,9(02):0.
XU Rui-jiang,HONG Xi-wei,YU Xiang-hua,et al.Surgical management for redislocation after open reduction of developmental dislocation of the hip in older children[J].Journal of Clinical Pediatric Surgery,2010,9(05):0.
[7]姜 海
汪 兵
吴永涛
苗武胜
吴 革.儿童肱骨远端骨骺分离的手术治疗[J].临床小儿外科杂志,2010,9(02):0.
Jiang hai,Wang bin,Wu yongtao,et al.The operative treatment in children’s distal humeral osteoepiphysis fracture.[J].Journal of Clinical Pediatric Surgery,2010,9(05):0.
[8]姜海吴永涛苗武胜梁晓军吴革汪兵张博皓.儿童移位型股骨颈骨折16例临床分析[J].临床小儿外科杂志,2010,9(03):0.
[9]王琪.儿童髂前上棘骨折27例疗效分析[J].临床小儿外科杂志,2010,9(03):0.
[10]王鹏高翟波罗淑颖.婴幼儿室间隔缺损合并肺动脉高压的外科治疗[J].临床小儿外科杂志,2010,9(03):0.
[11]杨维,任清华,秦红,等.儿童肝母细胞瘤精准肝切除手术效果评价[J].临床小儿外科杂志,2020,19(05):392.[doi:10.3969/j.issn.1671-6353.2020.05.004]
Yang Wei,Ren Qinghua,Qin Hong,et al.Evaluations of precise hepatectomy for pediatric hepatoblastoma[J].Journal of Clinical Pediatric Surgery,2020,19(05):392.[doi:10.3969/j.issn.1671-6353.2020.05.004]
备注/Memo
收稿日期:2019-08-07。
通讯作者:董瑞,Email:rdong@fudan.edu.cn